优化多参数磁共振成像靶向活检与临床显著前列腺癌检出:病灶周围取样的作用
研究纳入505例在Jules Bordet研究所接受系统活检(SB)和靶向活检(TB)的可疑MRI病灶(PI-RADS评分3-5)患者,回顾三维前列腺图确定含csPCa的系统穿刺芯与MRI指数病灶的距离。结果显示TB、SB和联合方法对csPCa的检出率分别为32%、25%和37%,TB联合10mm内病灶周围取样与联合方法检出率无差异(37% vs 35%,p=0.2);CHAID算法识别出三个风险组,低、中、高风险组漏诊csPCa的风险分别为2%、8%和29%。
要点
- TB、SB和联合方法对csPCa的检出率分别为32%、25%和37%。
- TB联合10mm内病灶周围取样与联合方法检出率无差异(37% vs 35%,p=0.2)。
- CHAID识别三个风险组,低、中、高风险组漏诊csPCa风险分别为2%、8%、29%。
核心结论
- 使用10mm边距的病灶周围活检模板似乎是联合方法的合理替代方案,csPCa检出率相当。
- 作者认为其风险分层可能进一步增强患者选择。
研究设计与样本
- 研究纳入2016年6月至2022年1月在Jules Bordet研究所接受SB和TB的可疑MRI病灶(PI-RADS评分3-5)的505例连续患者。
- 回顾患者特异性三维前列腺图,确定含csPCa的系统穿刺芯与MRI指数病灶之间的距离。
- 主要结局为每例患者的癌症检出率(CDR)和距MRI指数病灶每5mm间隔阳性穿刺芯的累积癌症分布率;次要结局为使用卡方自动交互检测(CHAID)机器学习算法识别10mm边距外存在csPCa的风险组。
主要发现
- TB、SB和联合方法对csPCa的CDR分别为32%、25%和37%。
- 联合方法检出csPCa多于TB(37% vs 32%,p < 0.001),但TB联合10mm内病灶周围取样与联合方法无差异(37% vs 35%,p = 0.2)。
- csPCa的累积癌症分布率在10mm边距处达到86%。
- CHAID算法识别三个风险组:PI-RADS3(低风险)、PI-RADS4或PI-RADS5且PSA密度<0.15 ng/ml(中风险)、PI-RADS5且PSA密度≥0.15 ng/ml(高风险)。
- 低、中、高风险组漏诊csPCa的风险分别为2%、8%和29%;避免10mm边距外的活检使19%的非csPCa未被检出。
关键数值与推荐
- TB、SB和联合方法对csPCa的CDR分别为32%、25%和37%。
- 联合方法vs TB:37% vs 32%,p < 0.001;TB联合10mm内病灶周围取样vs联合方法:37% vs 35%,p = 0.2。
- csPCa累积癌症分布率在10mm边距处为86%。
- 风险组:PI-RADS3为低风险;PI-RADS4或PI-RADS5且PSA密度<0.15 ng/ml为中风险;PI-RADS5且PSA密度≥0.15 ng/ml为高风险。
- 低、中、高风险组漏诊csPCa风险分别为2%、8%、29%。
临床怎么用
- 作者认为使用10mm边距的病灶周围活检模板似乎是联合方法的合理替代方案。
- 作者认为其风险分层可能增强患者选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The added-value of systematic biopsy (SB) in patients undergoing magnetic resonance imaging (MRI)-targeted biopsy (TB) remains unclear and the spatial distribution of positive cores relative to the MRI lesion has been poorly studied. The aim of this study was to determine the utility of perilesional biopsy in detecting clinically significant prostate cancer (csPCa). METHODS: We enrolled 505 consecutive patients that underwent SB and TB for suspicious MRI lesions (PI-RADS score 3-5) at Jules Bordet Institute between June 2016 and January 2022. Patient-specific tridimensional prostate maps were reviewed to determine the distance between systematic cores containing csPCa and the MRI index lesion. Primary outcomes were the cancer detection rate (CDR) per patient and the cumulative cancer distribution rate of positive cores for each 5 mm interval from the MRI index lesion. The secondary outcome was the identification of risk groups for the presence of csPCa beyond a 10 mm margin using the chi-square automated interaction detector (CHAID) machine learning algorithm. RESULTS: Overall, the CDR for csPCa of TB, SB, and combined method were 32%, 25%, and 37%, respectively. While combined method detected more csPCa compared to TB (37% vs. 32%, p < 0.001), no difference was found when TB was associated with perilesional sampling within 10 mm (37% vs. 35%, p = 0.2). The cumulative cancer distribution rate for csPCa reached 86% for the 10 mm margin. The CHAID algorithm identified three risk groups: (1) PI-RADS3 ("low-risk"), (2) PI-RADS4 or PI-RADS5 and PSA density <0.15 ng/ml ("intermediate-risk"), and (3) PI-RADS 5 and PSA density ≥0.15 ng/ml ("high-risk"). The risk of missing csPCa was 2%, 8%, and 29% for low-, intermediate- and high-risk groups, respectively. Avoiding biopsies beyond a 10 mm margin prevented the detection of 19% of non-csPCa. CONCLUSIONS: Perilesional biopsy template using a 10 mm margin seems a reasonable alternative to the combined method with a comparable detection of csPCa. Our risk stratification may further enhance the selection of patients.
引用
- Noujeim JP, Belahsen Y, Lefebvre Y, et al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. Prostate Cancer Prostatic Dis. 2022. PMID: 36509930. doi:10.1038/s41391-022-00620-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。